发明名称 |
Anti B7-H3 antibody |
摘要 |
An antibody exhibiting antitumor activity that binds to B7-H3, a functional fragment of the antibody, a pharmaceutical composition that includes the antibody or the functional fragment, methods for making the antibody or the functional fragment, methods for treating a tumor using the antibody or the functional fragment, and polynucleotides encoding the antibody or the functional fragment. |
申请公布号 |
US9371395(B2) |
申请公布日期 |
2016.06.21 |
申请号 |
US201213455021 |
申请日期 |
2012.04.24 |
申请人 |
Daiichi Sankyo Company, Limited |
发明人 |
Takahashi Shu;Matsuoka Tatsuji;Murakami Kenji;Takizawa Takeshi;Hirotani Kenji;Urano Atsushi;Fukuchi Keisuke;Yazawa Mitsuhiro |
分类号 |
C12P21/08;C07K16/00;C07K16/30;C07K16/28;A61K39/395;C07H21/00;C07K16/42 |
主分类号 |
C12P21/08 |
代理机构 |
Christensen O'Connor Johnson Kindness PLLC |
代理人 |
Christensen O'Connor Johnson Kindness PLLC |
主权项 |
1. An antibody characterized by having the following properties:
(a) specific binding to an IgC1 and/or IgC2 domain of B7-H3, (b) having a constant region that is a human constant region; (c) comprising CDRH1 consisting of an amino acid sequence comprising SEQ ID NO: 92, CDRH2 consisting of an amino acid sequence comprising SEQ ID NO: 93, and CDRH3 consisting of an amino acid sequence comprising SEQ ID NO: 94 as complementarity determining regions of the heavy chain and comprising CDRL1 consisting of an amino acid sequence comprising SEQ ID NO: 95, CDRL2 consisting of an amino acid sequence comprising SEQ ID NO: 96, and CDRL3 consisting of an amino acid sequence comprising SEQ ID NO: 97 as complementarity determining regions of the light chain; (d) having an antibody-dependent cell-mediated phagocytosis (ADCP) activity; and (e) having an in vivo antitumor activity against tumors expressing B7-H3 comprising SEQ ID NO: 6 or SEQ ID NO:10. |
地址 |
Tokyo JP |